U.S. General Merchandise and Department Stores Stock News

Clinical momentum and index changes frame Dianthus Therapeutics stock story Dianthus Therapeutics (DNTH) has kicked off its global Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis, while the stock was recently removed from several Russell value and growth benchmarks. The EMERGE trial will enroll about 195 acetylcholine receptor antibody positive generalized Myasthenia Gravis participants and compare subcutaneous claseprubart against placebo, with the Myasthenia Gravis...

Arbutus Biopharma stock has delivered a strong 126.4% return over the past three years, yet its current valuation checks and market multiples suggest the shares are not a clear bargain at recent levels. Over the last three years, Arbutus Biopharma has returned 126.4%, which puts extra focus on whether the current share price already reflects much of the good news investors are hoping for. Expectations around the company’s ability to turn its pipeline and research into durable cash flows can...

AZZ (AZZ) has opened fiscal 2027 with Q1 revenue of $448.5 million and basic EPS of $1.74, setting the tone for how its earnings story is evolving after a mixed year of growth and margin shifts. The company has seen quarterly revenue move from $421.9 million and EPS of $5.71 in Q1 2026 to $448.5 million and $1.74 in Q1 2027, against a backdrop where trailing 12 month EPS was $6.62 and net income was $198.4 million. This frames a results season in which investors are watching how profit...

Helen of Troy (HELE) opened fiscal Q1 2027 with revenue of US$402.1 million and basic EPS of US$1.54, while the trailing twelve months show revenue of US$1.8 billion and a basic EPS loss of US$17.87, highlighting the gap between the latest quarter and the broader period. Over the past few reported quarters, revenue has ranged from US$371.7 million to US$512.8 million and EPS has swung from a loss of US$19.65 to a profit of US$2.22. This sets the backdrop for how investors read this latest...

Index reshuffle puts Kaiser Aluminum in focus Kaiser Aluminum (KALU) reported record first quarter 2026 net sales, conversion revenues, net income and adjusted EBITDA, alongside guidance for further improvement this year, just as the stock shifted across several Russell index classifications. For investors, this combination of strong recent performance and index changes raises practical questions about how Kaiser Aluminum might fit within portfolios that track value, growth or defensive...

With the Federal Reserve turning hawkish again and inflation sitting at 4.2%, investors are rethinking where they want their money. Rising rates, volatile growth stocks, and a rotation toward more resilient earnings stories are reshaping the opportunity set. This article looks at how that backdrop and the recent Fed pivot could affect U.S. Financial Services Stocks, and why some large, financially healthy companies may be better positioned than others. Below, you will find 3 stocks from our...

Innovex International (INVX) has just been added to multiple Russell growth indexes. This event can reshape who holds the stock as index funds and benchmarked investors adjust their portfolios. See our latest analysis for Innovex International. Over the past year Innovex International has combined a 10.01% year to date share price gain with a 54.03% total shareholder return. However, the 30 day share price return is down 11.85%, and the recent index additions appear to be resetting near term...

With major indexes riding an AI-fueled surge and the Buffett indicator sitting at a very high level relative to GDP, many investors are wondering where genuine value still exists and where risks might be building. This article looks at how that backdrop could affect a group of stocks flagged by a Value Stocks screener, focusing on low P/E and P/B ratios and a possible discount to intrinsic value. Below, you will find 3 stocks that the recent market setup may treat as relative beneficiaries...

In recent months, AllianceBernstein Holding has advanced efforts to lift profitability through office relocations and other margin accretion measures, while broadening its private markets platform via partnerships and new products in private credit, real estate, and alternative strategies. This push into higher-fee private markets and operational efficiency has sharpened investor focus on how the firm may reshape its earnings mix and risk profile. Next, we’ll examine how AllianceBernstein’s...

Microchip Technology has made its MPLAB XC Pro Compilers and Machine Learning Development Suite available for free to all users worldwide. The move also covers its functional safety compilers, broadening access to tools for safety-critical and AI-enabled embedded applications. This shift is expected to widen adoption of Microchip’s microcontroller platforms and deepen engagement with its development ecosystem. For investors watching NasdaqGS:MCHP, this software decision adds an important...

After a strong first month as a public company, Quantinuum’s near 30% gain over the past 30 days sits alongside a sharp split in valuation signals, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples screen the stock as expensive. The question for investors is how to weigh that tension against early stage quantum computing expectations and the stock’s low overall value score. Quantinuum has risen 29.5% over the past month,...

Prologis (NYSE:PLD) has taken its proposed all stock combination with SEGRO public, releasing a new presentation to SEGRO shareholders. The company is urging SEGRO investors to press their board to enter takeover talks, while SEGRO's board continues to resist the deal. This move shifts the discussion from private boardroom talks to a wider shareholder audience, highlighting Prologis' commitment to a public engagement campaign. Prologis enters this phase of the saga with its stock at $141.0...

Lindsay stock is coming off a challenging stretch, with the share price down about 26% over 5 years, yet the current intrinsic value estimate from a Discounted Cash Flow (DCF) model points to meaningful upside compared with where the market is pricing it today. At the same time, earnings based multiples look roughly in line with peers, which sets up a tension between a seemingly cheap cash flow profile and a share price that does not screen as obviously mispriced on simpler metrics. Over 5...

Index removal puts Precigen stock in focus Precigen (PGEN) has been removed from several Russell value and small cap benchmarks, an index reshuffle that can prompt passive funds to rebalance and temporarily change trading volumes or pricing. See our latest analysis for Precigen. For context, Precigen's share price has a 30 day share price return of 55.74% and a year to date share price return of 29.91%, while the 1 year total shareholder return of 192.63% and 3 year total shareholder return...

Pagaya Technologies and Upgrade have expanded their partnership to bring Pagaya’s AI-driven credit decisioning to Buy Now, Pay Later offerings. The collaboration targets BNPL solutions for travel merchants, broadening Pagaya’s reach beyond personal loans. The development highlights a move into new asset classes for Pagaya’s platform, with potential implications for its client mix and revenue sources. Pagaya Technologies (NasdaqCM:PGY) is drawing fresh attention as it extends its AI credit...

Southwest Airlines and Korean carrier Air Premia have entered into their first-ever interline partnership. The agreement connects Air Premia routes from South Korea with more than 120 destinations across the Southwest Airlines network. The partnership opens new East Asia connectivity for Southwest customers and expands options for travelers originating in South Korea. For investors watching Southwest Airlines, ticker NYSE:LUV, this partnership introduces an additional international angle to...

Monte Rosa Therapeutics (GLUE) is in focus after a broad reshuffle of its index affiliations, as the stock was added to several Russell growth benchmarks while being removed from multiple value oriented Russell indexes. See our latest analysis for Monte Rosa Therapeutics. The index reshuffle comes after a sharp run in Monte Rosa Therapeutics' share price, with a 30 day share price return of 41.53% and a year to date share price return of 57.15%, alongside a one year total shareholder return...

Personalis stock has delivered a very large 3 year gain, yet the valuation checks still lean expensive, which puts the recent share price strength in tension with what the broader numbers suggest about value. Over the past 3 years, Personalis has returned roughly 5x, which is a very large move that raises the bar for what the current share price needs to justify. Future revenue growth and the path to stronger, more consistent cash flows can support today’s valuation. However, execution risks...

Halliburton stock has delivered a 79.3% return over the past five years, and the current checks still suggest the shares lean cheap rather than fully priced in. With fresh contracts in Iraq and mixed short term trading, investors are weighing how much of the story is already reflected in the valuation. A 79.3% five year return points to solid longer term shareholder gains, raising the question of how much upside may already be captured in Halliburton's current price. The recent agreement to...

In June 2026, Deluxe Corporation (NYSE: DLX) was added to both the Russell 2000 Defensive Index and the Russell 2000 Value-Defensive Index, highlighting its classification as a smaller-cap company with more defensive, value-oriented characteristics. This dual index inclusion can influence how institutional investors view Deluxe, potentially affecting demand for the shares as index-tracking funds and quantitatively driven portfolios adjust their holdings. Next, we’ll examine how Deluxe’s...

On 27 June 2026, Central Bancompany, Inc. was removed from the Russell 1000 Dynamic Index and added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, reshaping its index footprint among large-cap US equities. This reclassification into defensive-oriented benchmarks may influence how institutional investors perceive the bank’s risk profile and adjust their portfolio allocations. Now we’ll explore how Central Bancompany’s shift into Russell 1000 defensive indices affects...

Donaldson Company (DCI) is back in focus after fresh analysis pointed to weak constant currency revenue growth, soft demand and declining returns on capital, raising questions around the stock’s underlying earnings power. See our latest analysis for Donaldson Company. Despite the recent concerns around Donaldson Company’s growth profile, the stock is trading at $87.68 and has eased in the short term, with the share price falling 2.1% over the last day and 1.6% over the past quarter. At the...

Worthington Enterprises, Inc. (NYSE: WOR) was removed from the Russell 2000 Dynamic Index on 27 June 2026, a change that can influence how index funds and benchmarked investors allocate capital to the stock. At the same time, a fresh restricted stock grant to director William Bradley Southern under the 2025 Equity Plan ties board compensation more closely to future company performance and governance continuity. We’ll now examine how Worthington’s removal from the Russell 2000 Dynamic Index...

In the last week, the United States market has stayed flat, yet over the past 12 months, it has risen by an impressive 18%, with earnings expected to grow at a similar rate annually in the coming years. In this context of steady growth and optimistic projections, identifying stocks that are trading below their intrinsic value can offer investors potential opportunities for capitalizing on undervalued assets.